SCHEMBL3292237

SCHEMBL3292237

Cc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1.[LiH]

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.69
MEN1 O00255 2/20 0.69
LMNA P02545 2/20 0.69
KMT2A Q03164 2/20 0.69
FLT1 P17948 2/20 0.69
FLT4 P35916 2/20 0.69
KDR P35968 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
EGFR P00533 2/20 0.67
POLB P06746 1/20 0.61
PTGS1 P23219 1/20 0.60
PTGES O14684 1/20 0.60
ALDH1A1 P00352 3/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HTT P42858 1/20 0.59
TP53 P04637 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
CYP2C9 P11712 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5931087 0.98 PTGS2 (0.71) PTGS2MEN1LMNAKMT2AFLT1
SCHEMBL790393 0.92 PTGS2 (0.67) PTGS2MEN1LMNAKMT2AFLT1
SCHEMBL9176266 0.90 PTGS2 (0.78) PTGS2KMT2AFLT1FLT4KDR
SCHEMBL7774524 0.88 LMNA (0.72) PTGS2MEN1LMNAKMT2AFLT1
SCHEMBL7777675 0.86 LMNA (0.60) PTGS2MEN1LMNAKMT2AFLT1
SCHEMBL174010 0.86 FLT1 (0.77) PTGS2MEN1LMNAKMT2AFLT1
SCHEMBL10769381 0.84 PTGS2 (0.65) PTGS2MEN1LMNAKMT2AFLT1
SCHEMBL7647250 0.84 LMNA (0.74) PTGS2MEN1LMNAKMT2APTGES
SCHEMBL7774521 0.84 LMNA (0.74) PTGS2MEN1LMNAKMT2APTGES
SCHEMBL29011132 0.84 FLT1 (0.74) PTGS2MEN1LMNAKMT2AFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732365-B2 Enantioselective amination and etherification YALE UNIVERSITY (US) 2010-06-08 US disclosed
US-20070259774-A1 Enantioselective Phosphoramidite Compounds and Catalysts YALE UNIVERSITY (US) 2007-11-08 US disclosed
US-20060199728-A1 Enantioselective amination and etherification YALE UNIVERSITY (US) 2006-09-07 US disclosed
WO-2004024684-A2 ENANTIOSELECTIVE AMINATION AND ETHERIFICATION YALE UNIVERSITY (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259774-A1 Enantioselective Phosphoramidite Compounds and Catalysts AKR1C3, PCNA, AKR1C4 PTGS2 2581/4885MEN1 1734/4885LMNA 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.